The effect of a three-tier formulary on antidepressant utilization and expenditures

Journal of Mental Health Policy and Economics

Volumn 11, Issue 2, 2008, Pages 67-77

  Hodgkin, Dominic ^a   Thomas, Cindy Parks ^a   Simoni Wastila, Linda ^b   Ritter, Grant A ^a   Lee, Sue ^a  

^a BRANDEIS UNIVERSITY   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT;

ADULT; ARTICLE; COST CONTROL; DRUG CLASSIFICATION; DRUG COST; DRUG PREFERENCE; DRUG UTILIZATION; FEMALE; HEALTH CARE POLICY; HEALTH CARE QUALITY; HEALTH INSURANCE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; PRETEST POSTTEST DESIGN; SEX DIFFERENCE;

ANTIDEPRESSIVE AGENTS; COST SHARING; DEPRESSION; DRUG COSTS; DRUG UTILIZATION; FEMALE; FORMULARIES; HUMANS; INSURANCE CLAIM REVIEW; LOGISTIC MODELS; MALE; MANAGED CARE PROGRAMS; PATIENT COMPLIANCE; PRESCRIPTIONS, DRUG; REIMBURSEMENT, INCENTIVE; RESEARCH DESIGN; UNITED STATES;

EID: 45949109188     PISSN: 10914358     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Mark TL, Levit KR, Buck JA, Coffey RM, Vandivort-Warren R. Mental health treatment expenditure trends, 1986-2003. Psychiatr Serv 2007; 58:1041-1048.
2. Horgan CM, Garnick DW, Merrick EL, et al. (2004). Substance Abuse and Mental Health Services in Health Plans: Results From A Nationwide Study. Summary Report to Respondents. Brandeis University.
3. Fairman KA, Motheral BF, Henderson RR. Retrospective, long-term follow-up study of the effect of a three-tier prescription drug copayment system on pharmaceutical and other medical utilization and costs. Clin Ther 2003; 25(12):3147-3161.
4. Huskamp HA, Deverka PA, Epstein AM, Epstein RS, McGuigan KA, Frank RG. The effect of incentive-based formularies on prescription-drug utilization and spending. N Engl J Med 2003; 349(23):2224-2232.
5. Huskamp HA, Frank RG, McGuigan KA, Zhang Y. The Impact of a Three-Tier Formulary on Demand Response for Prescription Drugs. J Econ Manag Strategy 2005, 14(3): 729-753.
6. Huskamp HA, Deverka PA, Epstein AM, Epstein RS, McGuigan KA, Muriel AC, Frank RG. Impact of 3-Tier Formularies on Drug Treatment of Attention-Deficit/Hyperactivity Disorder in Children. Arch Gen Psychiatry 2005; 62(4): 435-441.
7. Joyce GF, Escarce JJ, Solomon MD, Goldman DP. Employer drug benefit plans and spending on prescription drugs. JAMA 2002; 288(14):1733-1739.
8. Kamal-Bahl S, Briesacher B. How do incentive-based formularies influence drug selection and spending for hypertension? Health Aff 2004; 23(1):227-236.
9. Nair KV, Wolfe P, Valuck RJ, McCollum MM, Ganther JM, Lewis SJ. Effects of a 3-tier pharmacy benefit design on the prescription purchasing behavior of individuals with chronic disease. J Manag Care Pharm 2003; 9(2):123-133.
10. Landon BE, Rosenthal MB, Normand SLT, Spettell C, Lessler A, Underwood HR, Newhouse JP. Incentive formularies and changes in prescription drug spending. Am J Manag Care 2007; 13(2); 360-369.
11. Motheral B, Fairman KA. Effect of a three-tier prescription copay on pharmaceutical and other medical utilization. Med Care 2001; 39(12):1293-1304.
12. Rector TS, Finch MD, Danzon PM, Pauly MV, Manda BS. Effect of tiered prescription copayments on the use of preferred brand medications. Med Care 2003; 41(3):398-406.
13. Landsman PB, Yu W, Liu X, Teutsch SM, Berger ML. Impact of 3-tier pharmacy benefit design and increased consumer cost-sharing on drug utilization. Am J Manag Care 2005; 11(10):621-8.
14. Goldman DP, Joyce GF, Escarce JJ, Pace JE, Solomon MD, Laouri M, Landsman PB, Teutsch SM. Pharmacy benefits and the use of drugs by the chronically ill. JAMA 2004; 291(19): 2344-2350.
15. Berndt ER, Frank RG, McGuire TG. Alternative Insurance Arrangements and the Treatment of Depressions: What are the Facts? Am J Manag Care 1997; 3: 243-250.
16. Huskamp HA. Managing psychotropic drug costs: will formularies work? Health Aff 2003; 22(5):84-96.
17. Lingain R, Scott J. Treatment non-adherpnce in affective disorders. Acta Psychiatr Scand 2002; 105(3):164-172.
18. Demyttenaere K. Compliance and acceptance in antidepressant treatment. Int J Clin Pract SuppI 2001; 5(1), p29-p35.
19. Ornstein S, Stuart G, Jenkins R. Depression diagnoses and antidepressant use in primary care practices: a study from the Practice Partner Research Network (PPRNet). J Fam Pract 2000; 49(1): 68-72.
20. Larson MJ, Miller K, Fleming KJ. Treatment with Antidepressant Medications in Private Health Plans. Adm Policy Ment Health 2007; 34(2): 116-126.
21. Cook TD, Campbell DT (1979). Quasi-experimemation: design and analysis issues forfield settings. Boston: Houghton-Mifflin.
22. Meyer, Bruce D. Natural and quasi-natural experiments in economics. Journal of Business and Economic Statistics 1995; 13(2): 151-162.
23. Zhao Y, Ash, AS, Ellis RP. Predicting Pharmacy Costs and Other Medical Costs Using Diagnoses and Drug Claims. Med Care 2005; 43(1):34-43.
24. DxCG Risk Adjustment Software: Analytic Guide Release 6.0 (2001). Boston MA: DxCG Inc.
25. Duan N, Manning WG, Morris CN, Newhouse JP. A comparison of alternative models of the demand for medical care. Journal of Business and Economic Statistics 1983; 1: 114-126.
26. Ai C and Norton EC. Interaction terms in logit and probit models. Economic Letters 2003; 80:123-129.
27. Liang K-Y, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika 1986; 73: 13-22.
28. Tooze JA, Grunwald GK, Jones RH. Analysis of repeated measures data with clumping at zero. Stat Methods Med Res 2002; 11:341-355.
29. Duan N. Smearing estimate: A nonparametric retransformation method. JASA 1983; 78(383):605-610.